Genelux Corporation (GNLX)
GNLX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/0001493152-26-011616-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GNLX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001231457 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $8K |
| Net income | -$32.1M |
| Operating income | -$33.2M |
| Net margin | -401812.5% |
| Operating margin | -415175.0% |
| Revenue growth | 0.0% |
| Cash | $5.3M |
| Total assets | $19.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 10858.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-08-13 |
| Cash and burn | $9.2M cash; operating cash flow -$6.3M a quarter. | Report 2026-06-30 |
| Shares outstanding | 45,245,335 (2026-08-11); 37,773,443 a year earlier; 26,182,892 three years earlier. | Cover page 2026-08-11 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-03-19 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Weinberg & Company, P.A., Los Angeles, California, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $359K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$9.5M | -$6.4M | $9.2M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$8.9M | -$6.1M | $9.3M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2025 2025-12-31 | Not filed | -$9.2M | -$6.2M | $5.3M | No debt tags | $8K | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | Not filed | -$8.0M | -$6.6M | $4.7M | No debt tags | Needs four quarters | 10-Q 2025-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$7.5M | -$7.1M | $6.5M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$7.5M | -$5.4M | $16.2M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | $0 | -$9.0M | -$4.3M | $8.6M | No debt tags | $8K | 10-K 2026-03-19 |
| Q3 2024 2024-09-30 | $0 | -$6.5M | -$5.7M | $6.1M | No debt tags | $8K | 10-Q 2025-11-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-19 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-06-22 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 363 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.8% |
| 1 month | -26.0% |
| 3 months | -29.1% |
| Year to date | -57.2% |
| 1 year | -66.2% |
| From 52-week high | -66.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NKTX | Nkarta Inc. | $1.21 | +1.68% | $86.8M |
| KZIA | Kazia Therapeutics Limited | $5.60 | -15.41% | $87.1M |
| RLYB | Rallybio Corporation | $15.43 | -1.88% | $86.4M |
| HURA | TuHURA Biosciences Inc. | $1.33 | -4.32% | $87.5M |
| ANIX | Anixa Biosciences Inc. | $2.55 | -2.67% | $88.6M |
| PMVP | PMV Pharmaceuticals Inc. | $1.19 | -6.30% | $89.9M |
| RTSN | Retension Pharmaceuticals Inc. | $11.46 | -6.60% | $90.3M |
| PLYX | Polaryx Therapeutics Inc. | $1.67 | -6.99% | $83.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier